Company News
10 Apr
AstraZeneca confirms new EU approval for 'Lynparza'
AstraZeneca and its partner Merck & Co announced on Wednesday that the European Commission has approved 'Lynparza' (olaparib) as a monotherapy for the treatment of adult patients with germline BRCA1 and 2-mutations (gBRCAm), and who have human epidermal growth factor receptor 2 (HER2)-negative locally-advanced or metastatic breast cancer.
10 Apr
Dunelm sees FY at top end of forecasts after solid Q3
Homewares retailer Dunelm said total like-for-like (LFL) revenue for the third quarter increased by 12. 5%, continuing the growth trend from the first half of the year.